Vargatef
What Vargatef is used for
Vargatef is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Vargatef
- Active substance
- nintedanib
- Disease area
- Carcinoma, Non-Small-Cell Lung
- Medicine group
- Antineoplastic agents, protein kinase inhibitors
- ATC code
- L01EX09
- Marketing authorisation holder
- Boehringer Ingelheim International GmbH
- Authorised in the EU since
- 2014
Official information
In India
- Nintedanib: 24 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Vargatef used for?
Vargatef is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy.
What is the active substance in Vargatef?
Vargatef contains nintedanib.
Who makes Vargatef?
The EU marketing authorisation holder is Boehringer Ingelheim International GmbH.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU